Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997.

J Infect Dis

Department of Epidemiology and Public Health, Division of Epidemiology of Microbial Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.

Published: March 2005

A population-based serosurvey was performed to determine the seroprevalence of antibodies to Ebola virus (EBO) in a region that has experienced multiple epidemics of EBO hemorrhagic fever. Of 2533 residents in 8 villages, serum samples from 979 (38.6%) were tested by enzyme-linked immunosorbent assay for immunoglobulin (Ig) G and IgM antibodies to Ebola-Zaire (EBO-Z) virus. Fourteen samples (1.4%) were found positive for IgG antibodies, and 4 of these (.4%) were samples from survivors of an epidemic of EBO hemorrhagic fever. Seroprevalence based on the remaining 10 IgG-seropositive individuals with no history of exposure to EBO was 1.0% (exact binomial 95% confidence interval, 0.5%-1.9%). No serum samples were found positive for IgM antibodies to EBO-Z virus. The low seroprevalence suggests that, outside of recognized outbreaks, human exposure to EBO in this epidemic zone is rare.

Download full-text PDF

Source
http://dx.doi.org/10.1086/427994DOI Listing

Publication Analysis

Top Keywords

low seroprevalence
8
igg antibodies
8
antibodies ebola
8
ebola virus
8
epidemic zone
8
ebo hemorrhagic
8
hemorrhagic fever
8
serum samples
8
igm antibodies
8
ebo-z virus
8

Similar Publications

An incursion and outbreak of Japanese encephalitis virus (JEV) was reported in Australia in 2021 and 2022, respectively. There was speculation that JEV may have been circulating in Australia unknowingly prior to the detection. In this study, we determined sero-prevalence and transmission of West Nile virus (WNV), Murray Valley encephalitis virus (MVEV) and JEV, prior to and post JEV incursion in a sentinel equine population in south-east Queensland (SEQ), Australia, using blocking ELISAs (screening test) and virus neutralisation test (confirmatory).

View Article and Find Full Text PDF

Seroprevalence of specific antibodies to Treponema pallidum in blood donors with DNA confirmation of seropositivity.

Cell Mol Biol (Noisy-le-grand)

January 2025

Swedish Board Member of General Surgery, Kurdistan Higher Council of Medical Specialties, Erbil, Iraq.

The rising global incidence of syphilis underscores the risk of transmission through blood transfusions. Treponema pallidum, the pathogen responsible for syphilis, represents a major public health challenge. Accurate detection is essential for controlling the disease, particularly in asymptomatic blood donors.

View Article and Find Full Text PDF

BackgroundThe first Corona Monitoring Nationwide (RKI-SOEP) study (October 2020-February 2021) found a low pre-vaccine SARS-CoV-2 antibody seroprevalence (2.1%) in the German adult population (≥ 18 years).AimThe objective of this second RKI-SOEP (RKI-SOEP-2) study in November 2021-March 2022 was to estimate the prevalence of SARS-CoV-2-specific anti-spike and/or anti-nucleocapsid (anti-N) IgG antibodies (combined seroprevalence), past infection based on infection-induced seroprevalence (anti-N), and basic immunisation (at least two antigen contacts through vaccination or infection) in individuals aged ≥ 14 years.

View Article and Find Full Text PDF

Goats are the one of the most susceptible domestic species to toxoplasmosis affecting animal health and production. The present study aimed to determine the seroprevalence of T. gondii infection in dairy goats from Rio de Janeiro, Brazil, as well as to evaluate associated risk factors, parasitic DNA detection in raw goat milk samples, and attempts to isolate the parasite from raw goat milk samples.

View Article and Find Full Text PDF

Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a recently emerged tickborne virus in east Asia with over 18,000 confirmed cases. With a high case fatality ratio, SFTSV has been designated a high priority pathogen by the WHO and the NIAID. Despite this, there are currently no approved therapies or vaccines to treat or prevent SFTS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!